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Among kidney transplant recipients, the treatment of choice for acute T cell-mediated
rejection (TCMR) with pulse steroids or antibody protocols has variable outcomes.
Some rejection episodes are resistant to an initial steroid pulse, but respond to subse-
quent antibody protocols. The biological mechanisms causing the different therapeutic
responses are not currently understood. Histological examination of the renal allograft is
considered the gold standard in the diagnosis of acute rejection. The Banff Classification
System was established to standardize the histopathological diagnosis and to direct
therapy. Although widely used, it shows variability among pathologists and lacks criteria
to guide precision individualized therapy. The analysis of the transcriptome in allograft
biopsies, which we analyzed in this study, provides a strategy to develop molecular
diagnoses that would have increased diagnostic precision and assist the development
of individualized treatment. Our hypothesis is that the histological classification of TCMR
contains multiple subtypes of rejection. Using R language algorithms to determine
statistical significance, multidimensional scaling, and hierarchical, we analyzed differential
gene expression based on microarray data from biopsies classified as TCMR. Next,
we identified KEGG functions, protein–protein interaction networks, gene regulatory
networks, and predicted therapeutic targets using the integrated database Consesnsus-
PathDB (CPDB). Based on our analysis, two distinct clusters of biopsies termed TCMR01
and TCMR02 were identified. Despite having the same Banff classification, we identified
1933 differentially expressed genes between the two clusters. These genes were further
divided into three major groups: a core group contained within both the TCMR01 and
TCMR02 subtypes, as well as genes unique to TCMR01 or TCMR02. The subtypes
of TCMR utilized different biological pathways, different regulatory networks and were
predicted to respond to different therapeutic agents. Our results suggest approaches
to identify more precise molecular diagnoses of TCMR, which could form the basis for
personalized treatments.
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INTRODUCTION
An important goal in medicine is to develop precision therapies
specific to each individual to deliver personalized medicine. As
eloquently stated by Sir William Osler over 100 years ago, “vari-
ability is the law of life, and as no two faces are the same, so no
two bodies are alike, and no two individuals react alike and behave
alike under the abnormal conditions we know as disease.” Since
the introduction of cyclosporine in the late 1980s, the therapeutic
protocols for many patients in clinical transplantation have been
based on three types of immunosuppressive drugs: a calcineurin
inhibitor, an antimetabolite, and a steroid. More recently, an
array of new agents including biological agents have emerged
or are entering investigational study. In addition, protocols that
are calcineurin inhibitor free or steroid sparing have also been
developed. Given the increasing number of therapeutic agents
and potential protocols and the limited number of transplant
patients, it is not tractable to evaluate all of the potential thera-
peutic permutations in prospective clinical trials. Furthermore, a
strategy is needed to precisely identify the optimal therapy to apply
personalized medicine for each individual patient based on each
patient’s genotype and phenotype (1–7).
Since its development in 1993, the Banff Classification has
served as a valuable tool in the diagnosis of allograft rejection and a
guide for clinical management. The first Banff classification stan-
dardized the histopathological criteria to diagnose rejection into
six major categories based on the histopathological findings (8):
(1) normal, (2) hyperacute, (3) borderline mild tubulitis, (4) acute
rejection, (5) chronic allograft nephropathy (CAN), (6) other
changes not due to rejection. A numerical grading was introduced
for each of the renal compartments. This classification created a
framework for further changes and modifications in subsequent
updates of the Banff classification. Despite the success and huge
positive impact this classification had on transplant medicine, it
also had limitations. The major weaknesses are the substantial
variability among pathologists and the lack of an external valida-
tion tool (9). The reproducibility of the Banff classification was
assessed with a Kappa statistics scoring system (10–12). These
studies showed a moderate reproducibility score for diagnostic
classification, whereas the numerical grading of tubulitis had an
extremely low kappa score indicating low reproducibility (10).
Identifying a correlation between the Banff classification and graft
survival has also been a challenge. In 2015, Krisl et al. followed
182 patients who developed a rejection episode for a median
of 527 days. They noted no difference in death censored graft
survival in the first 6months after transplantation between the
acute cellular rejection grades IA, IB, IIA, and IIB. They also
noted no difference between the early and late Banff IA or IB
classifications. However, the same histological classification of
IIA had a significant difference in graft survival if it occurred
late (after 6months) versus early (13). These differences suggest
that the different subtypes do not represent a graded severity
score that correlates with graft survival, but rather a different type
of rejection. In another study, Wu et al. followed 270 patients
with rejection and noted no significant difference in the graft
survival between TCMR I, II, or III. However, they noted worse
graft outcomes in patients with vascular involvement regardless
of the degree of the timing or the degree of interstitial or tubular
involvement (14). Again, this analysis suggests different subtypes
of TCMR that are not precisely captured by the Banff classifica-
tions. In summary, these studies demonstrate the limitations of
the Banff classification in grading the severity of rejection and in
predicting outcomes.
Our overall hypothesis is that the histological diagnosis of
TCMR as defined by the Banff classification of kidney transplant
biopsies contains multiple subtypes of rejection involving differ-
ent biological pathways and functions. To address these goals, in
this report, we use a systems biology approach to provide a proof of
principle analysis that identifies potential therapeutic agents that
target specific subtypes of T cell-mediated rejection (TCMR).
The basis of our approach is the analysis of the transcriptome
in allograft biopsies. The analysis of differential expression of
mRNA has several advantages. First, genome wide assays of the
transcriptome are relatively quick, quantitative, and reproducible.
In contrast, other “omic” technologies, in particular proteomics
and metabolomics can be technically more challenging and not
genome wide. Second, the level of gene expression quantitated
in the transcriptome reflects multiple effects including genomic,
epigenetic, metagenomic, and environmental influences and thus
integrates the effect of multiple biological regulatorymechanisms.
Based on these considerations, analysis of the transcriptome,
which is utilized in this study, is a quantitative, reproducible, and
cost-effective approach to assay a genome wide response.
To interpret genome wide data, the application of systems biol-
ogy methods that analyze pathways and networks of molecules
in an “interactome” increases confidence in functional biologi-
cal interpretations compared with the reductionist approach of
analysis of isolated molecular interactions. In our analysis, we
first identified the significant changes in the transcriptome of
microarray data in a public database of kidney transplant biopsies
that were classified as TCMR or control. After excluding outliers
using multidimensional scaling (MDS), which is an essential step
that supports precision analysis, we identified subtypes of TCMR
using unsupervised hierarchical clustering. For each subtype, we
constructed a protein–protein interaction (PPI) network, a gene
regulatory network, and a KEGG pathway analysis, which illu-
minated interaction networks, signaling pathways, and regulatory
mechanisms. In addition, we analyzed the DrugBank database of
candidate drugs to identify putative therapeutic agents that would
be specific for each subtype of TCMR.
MATERIALS AND METHODS
Data
The data files were downloaded from NCBI through R, ver-
sion 3.10, using a Bioconductor package, GEOquery (15, 16).
The dataset contains the microarray expression from an HG-
U133_Plus_2 Affymetrix Human Genome array. Gene expres-
sion was given as log2 fold change against controls. The dataset
included 202 kidney biopsies taken from renal transplant patients
undergoing biopsies for cause (17). The expression and pheno-
typic data can be found on the Gene Expression Omnibus (GEO)
database, using GEO ascension number (GSE21374) (18).
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The initial data set of 202 kidney biopsies included eleven
diagnoses based upon pathology report. These biopsies included
rejection diagnoses of antibody-mediated rejection (ABMR),
acute tubular necrosis (ATN), BK virus, borderline, CAN, cal-
cineurin inhibitor toxicity (CNIT), glomerulonephritis (GN),
tubular atrophy/interstitial fibrosis (TAIF), T cell-mediated rejec-
tion (TCMR), and transplant glomerulopathy (TGP). There were
143 samples taken from 85 patients that underwent renal trans-
plant. Eight additional kidney biopsies were taken from normal,
native kidneys from patients undergoing nephrectomy for renal
cell carcinoma. Finally, 51 additional transplant biopsies were
added as a validation set.We focused on the largest cohort, TCMR,
using the renal nephrectomy samples as a baseline control.
Statistical Methods
An analysis pipeline was created in the R language statistical
and graphing environment (19). First, we normalized the 54,675
Affymetrix probe sets by Z-score and filtered the data based on
the scaled expression level>0.12 and coefficient of variation (CV),
which selected 6,473 genes that showed high expression and high
CV. Next, we identified outlier samples using MDS. Samples with
an intracentroid distance >2 SD greater than the mean were
classified as outliers and removed from further analysis. To iden-
tify subtypes of TCMR, we performed unsupervised hierarchical
clustering using the stats package. The clusters were evaluated by
connectivity, Dunn, and Silhouette index, which identified two
subtypes of TCMR. Differential gene expression was determined
by student’s t test (p< 0.05). Correction for multiple testing was
performed by false discovery rate algorithm (fdr<0.05).
Molecular Interaction Analysis
We used the ConsesnsusPathDB (CPDB), hosted by the Max
Plank Institute of Molecular Genetics (20). CPDB combines 32
public resources for biological interactions including the KEGG,
BIND, DrugBank and MINT databases. For each database, we
analyzed TCMR01, TCMR02, and core gene list independently.
Over-representation analysis was performed in CPDB for
KEGG pathways. The resulting enriched pathway-based sets
included a minimum of two input genes with a hypergeometric
test p-value of 0.01. Edges between KEGG pathways included at
least a 30% overlap between connecting nodes.
We used CPDB induced network module analysis of high-
confidence PPI, gene regulatory interactions, and drug-target
interactions.
Network Visualization
Network data were visualized with the imaging platform
Cytoscape (21).
RESULTS
Defining Subtypes of T Cell-Mediated
Rejection
To identify subtypes of TCMR rejection in kidney allografts,
we analyzed all samples classified as TCMR rejection (and
nephrectomy controls) using the Banff histological classification
of rejection in a database of kidney transplant biopsies (GSE
21374). First, we filtered microarray expression data based on the
CV>0.12. Next, we analyzed the 31 samples classified as TCMR
using MDS to identify statistical outliers among the samples
(Figure 1).Wedefined samples as outliers thatweremore than two
SD from the medoid. Based on this criterion, we classified three
samples (T.31, T.22, and T.13) as outliers. The remaining samples
were analyzed by hierarchical clustering using stats Package in R
language (Figure 2B). To determine the optimal number of clus-
ters, we analyzed the dendrogram based on connectivity, Dunn
Index, and Silhouette Index (Table S1 in SupplementaryMaterial).
All three methods supported partitioning the results into two
distinct clusters that we termed “TCMR01” and “TCMR02.”
Hierarchical Clustering Based on
Molecular Heterogeneity
Next, we calculated the mean expression levels of genes in
TCMR01, TCMR02, NEPH01 (nephrectomy control), and
NORM01 (biopsies pathologically classified as normal) and
analyzed the subtypes with hierarchical clustering (Figure 2A).
NEPH01 and NORM01 were similar based on proximity in
the dendogram. Interestingly, TCMR01 was more dissimilar
than TCMR02 from the NEPH01 and NORM01 subtypes
suggesting that TCMR01 exhibited the more extreme subtype. To
determine if the two clusters contained differentially expressed
genes, we performed t-tests between TCMR01 and TCMR02,
which identified 1933 genes that were significantly differentially
expressed (fdr<0.05) (Table S2 in SupplementaryMaterial). Thus,
although the TCMR01 and TCMR02 subtypes of rejection had
similar histological diagnoses, they were markedly heterogeneous
at the molecular level of gene expression.
Functional Differences Between Subtypes
of T Cell-Mediated Rejection
Based on the large number of differentially expressed genes in the
TCMR01 and TCMR02 subtypes, we investigated whether the
two subtypes had different biological functions. We selected
three groups of differentially expressed genes: a core group that
was differentially expressed in both subtypes and groups that
were uniquely differentially expressed in either TCMR01 or
TCMR02. Next, we identified the KEGG pathways that were
significantly associated with each group of genes (Figure 3;
Table S3 in Supplementary Material). In the core group, defined
as the genes common to both TCMR01 and TCMR02, the
pathway with the highest significance was “allograft rejection”
(q< 9.67E 16), which supported the validity of our approach.
Additional highly significant pathways included “graft-versus-
host disease” (q< 2.10E 15), “antigen processing and presenta-
tion” (q< 2.10E 15), “type I diabetes mellitus” (q< 2.90E 15),
“autoimmune thyroid disease” (q< 4.75E 14), “viral myocardi-
tis” (q< 9.44E 14), “phagosome” (q< 1.27E 10), and “cell
adhesion molecules” (q< 3.37E 09). All of the significant path-
ways share a strong pathological immune response and the emer-
gence of pathways associated with autoimmunity, allergy and
infections in addition to alloimmunity are due to the over-
lap in the genes involved in these immune processes. Impor-
tantly, it is notable that the significance level of “allograft
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FIGURE 1 | Analysis of potential sample outliers with multidimensional scaling (MDS). We analyzed 31 samples with a pathological diagnosis of
T cell-mediated rejection (TCMR) in the kidney transplant database (GSE21374). Using multidimensional scaling of the gene expression data, we identified samples
with an intracentroid distance z-score >2 (represented by the dashed lines) which included three samples (T13, T22 and T31).
FIGURE 2 | (A) Comparison of TCMR01 and TCMR02 with the normal and nephrectomy controls. Unsupervised hierarchal clustering of TCMR01, TCMR02,
NEPH01 (nephrectomy) and NORM01 (normal biopsy samples). (B) The subtypes of T cell-mediated rejection (TCMR) classified by unsupervised hierarchical
clustering. After filtering the initial 54,675 Affymetrix probe sets based upon scaled expression and coefficient of variation, we identified two distinct groups of
T cell-Mediated Rejection: TCMR01 (left) and TCMR02 (right). The two sub-diagnoses were differentiated by 1933 significant genes based upon false-discovery rate
corrected p-values of 0.05.
rejection” is more than an order of magnitude more signif-
icant than the other pathways. In addition to immune pro-
cesses, we also detected significant metabolic pathways including
“tryptophan metabolism” (q< 0.000152), “histidine metabolism”
(q< 0.000194), “glycine, serine, and threonine metabolism”
(q< 0.00154), “fatty acid degradation” (q< 0.00242), “valine,
leucine, and isoleucine degradation” (q< 0.00285), “arginine and
proline metabolism” (q< 0.0074), and “fructose and mannose
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FIGURE 3 | Functional analysis of the KEGG pathways in the core (A), TCMR01 (B), and TCMR02 (C) subtypes. We identified KEGG pathways for the
significantly modulated genes in the three subtype. The five main functional pathways are presented in the figures. Allograft rejection pathways along with other
immune pathways are highly expressed in the core group, whereas the TCMR01 is rich with metabolic pathways. Complement and coagulation cascades seem to
be uniquely expressed in the TCMR02 group. The numbers on the lines represent the p-values and are all significant with a value of <0.05. The data was analyzed
with CDBP and the networks were visualized with Cytoscape.
metabolism” (q< 0.00864) that may be important in modu-
lating the immune response and could potentially serve as
novel therapeutic targets. In contrast to the core response,
the pathways associated with the TCMR01 subtype predomi-
nantly involved metabolism. The pathways represented a diverse
array of metabolic functions ranging from the citrate cycle
to amino acid metabolism to glyoxylate metabolism to extra-
cellular matrix interaction. The TCMR01 subtype did not
contain any significant pathways directly involving immune func-
tions, whereas the TCMR02 included a number of immune
responses associated with infections, complement and coag-
ulation cascades and natural killer cell-mediated cytotoxicity.
Based on the KEGG pathway analysis, our data indicate that
the TCMR01 and TCMR02 subtypes of rejection, in addi-
tion to differential gene expression, have different biological
functions.
Protein Interactions
To investigate the mechanisms regulating the different biolog-
ical functions in the different subtypes of rejection, we con-
structed PIP graphs (Figure 4). Overall, it is apparent that the
PIPs include subnetworks involved a diverse array of biological
processes. For example, the core genes common to both sub-
types mediated upregulation of HLA class I and II molecules,
expression of cytoskeletal molecules including tubulin, fibulin,
and actin-binding proteins, proteasome components, IFNγ recep-
tor, and interferon response factors and regulators of stress and
energy production. The TCMR01 subtype upregulated collagen
and metabolic enzymes. In contrast, the TCMR02 subtype had
increased expression of RANTES, complement components of
C1q, matrix protein keratin 19, cytoskeletal components of actin
and tropomyosin, proteasome components, and GTP-binding
proteins.
Transcription Factors
Next, we analyzed the mechanisms regulating the differential
gene expression by focusing on the regulation of gene expres-
sion by transcription factors (Figure 5). In the core genes, we
detected STAT1, JUND, HNF1, and IKB. In contrast, transcrip-
tion factors unique to the TCMR01 subtype include STAT3,
FRA, JUNB, MYC, GR, and ZIC1, whereas transcription fac-
tors unique to the TCMR02 subtype include STAT2, MAFb,
Kaiso, EGR1, and CEBPd. In addition, FKBP5, which is a
cis–trans prolyl isomerase that mediates calcineurin inhibition
and binds the immunosuppressants, FK506 and rapamycin is
upregulated in TCMR02. The differential abundance of tran-
scription factors, which are known to be regulated by dif-
ferent cytokines and growth factors, suggest the activation of
different signal transduction pathways in the two rejection
subtypes.
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FIGURE 4 | Analysis of the protein–protein interaction networks in the core, TCMR01 and TCMR02 subtypes. We identified the protein–protein interaction
networks of the significantly modulated genes for the core, TCMR01 and TCMR02. Each node represents a protein from the input gene list, and each edge shows a
high-confidence protein–protein interaction (PPI). The three subnetworks show how the TCMR subtypes are vastly different on a molecular level. The data was
analyzed with CDBP and the networks were visualized with Cytoscape.
Drug–Target Interactions
Given the different transcription factor and effector mechanisms
functioning in the different subtypes, we investigated the notion
that different treatment modalities would be more precise for
each subtype of rejection. An analysis of the potential therapeutic
drugs effective against the core genes containing both TCMR01
and TCMR02 phenotypes identifies multiple drugs that have
been studied in clinical trials or FDA approved as treatment
for transplantation including Muromonab (OKT3), Epothilone
B, Epothilone D, Gemtuzumab ozogamicin, Ibritumonab, PDX,
Fucose, Sulfasalazine, and TNRF2 (cleaved) (Figure 6). In an
analysis of drugs that may be more precisely targeted to each
subtype, we identified, as expected based on the PIP, drugs tar-
geted to metabolic processes in TCMR01. In contrast, among the
drugs targeted to TCMR02, we detected 15 agents in clinical use
or that have undergone clinical trials including Alemtuzumab,
Alefacept, and Gemtuzumab. In addition, several potential cancer
drugs had potential targets in the TCMR02 subtype. These results
suggest that our analytical methods may identify therapeutic
drugs that would be more precise in the treatment of subtypes
of TCMR.
DISCUSSION
In this study, we investigated the hypothesis that the histo-
logical classification of TCMR contained multiple subtypes of
rejection involving different biological pathways and functions.
Our analysis using systems biology approaches identified two
distinct subtypes of rejection, TCMR01 and TCMR02. We con-
firmed the validity of the clusters by three criteria (connectiv-
ity, Dunn index, and Silhouette index). A direct comparison of
gene expression between the two subtypes identified 1933 genes
that were significantly differentially expressed (fdr<0.05) despite
the fact that all samples had a similar histological diagnosis.
We suggest that the significance of our study is the demon-
stration of the proof of principle that analysis of the transcrip-
tome may be a more precise classifier than current histological
diagnoses.
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FIGURE 5 | Analysis of the gene regulatory interaction networks in the core, TCMR01 and TCMR02 subtypes. We identified putative gene regulatory
networks in the core, TCMR01 and TCMR02 based on the significantly modulated genes (blue nodes). The contrasting elements in the two subnetworks show that
the TCMR subtypes are different on the level of transcriptional regulation. The data was analyzed with CDBP and the networks. Gray nodes represent products.
Purple nodes represent transcription factors. Green nodes represent repressors.
We identified three groups of differentially expressed genes that
composed the core response defined as the genes common to
both subtypes and groups unique to each subtype of rejection.
A functional analysis of gene expression data using the KEGG
database identified different functions for each group (18). For
example, the core functions that were based on genes differentially
expressed in both subtypes included immune functions involved
in alloimmune responses. In fact, the most significant pathway
was “allograft rejection,” which strongly supports the validity of
our analysis. In contrast, the KEGG pathways associated with
the unique genes in TCMR01 included predominantly metabolic
functions (e.g., glyoxylate metabolism, amino acid metabolism,
and citrate cycle), which may indicate parenchymal damage to
the graft. The pathways unique in TCMR02 included complement
and coagulation cascades and natural killer cell cytotoxicity. Thus,
at the functional level our analysis demonstrated core functions
common to both subtypes as well as unique functions specific
for either TCMR01 or TCMR02. The unique functions suggest
potential strategies to develop precision treatments, potentially
applicable to transplant rejection.
We analyzed the KEGG database, which is collated on current
knowledge (22). It is notable that multiple pathways activated in
the core genes were either immune or metabolic processes. For
example, another immune pathway was graft-versus-host disease;
however, the patients did not have clinical evidence of graft-
versus-host disease. Importantly, this pathway was more than one
order of magnitude less significant than allograft rejection and a
manual inspection of the relevant genes in these pathways shows
that the identical genes can participate in multiple broad disease
focused KEGG pathways, such as allograft rejection or GVHD.
Thus, when evaluating these disease pathways, it is essential to
include additional criteria such as clinical correlates or metadata.
When considering the more biologically fundamental pathways
(e.g., phagosome, histidine metabolism, proteasome, fatty acid
degradation, valine degradation, endocytosis, natural killer cell
cytotoxicity, arginine metabolism, and fructose metabolism), we
observed that the relevant genes are activated.
We also investigated potential mechanisms that mediated the
disease processes identified by KEGG pathways. At the level
of protein interactions, the core response includes anticipated
immune molecules including HLA Class I and II, CD8, and com-
plement receptors. In addition, we identified antigen processing
and presenting molecules (HLA-DMβ, proteasome, and CD74)
cytoskeletal proteins (tubulin, actin). In contrast, the TCMR01-
specific proteins included numerous metabolic mediators and
collagen proteins suggesting possible wound healing and fibrosis.
The TCMR02-specific proteins included C1q complement pro-
teins, FKBP, RANTES, and cathespin O. At the level of differential
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FIGURE 6 | Analysis of the network of potential drug-targets. Potential drugs (red nodes) that target proteins (gray nodes) that were significantly modulated in
the core, TCMR01 and TCMR02 subtypes were identified. The majority of these drug-target relationships have been curated by the literature associated by
DrugBank. The data was analyzed with CDBP and the networks were visualized with Cytoscape.
expression of transaction factors, there were differences among
the three groups. Interestingly, an analysis of the STAT molecules
showed that the core response included STAT1, TCMR01 included
STAT3, and TCMR02 included STAT2 indicating the activation of
different signal transduction pathways in each group.
Considered as a whole, we emphasize that the most compelling
observation of our systems biology approach is the demonstra-
tion that diverse biological mechanisms are coordinated in an
integrated response in allograft rejection. As expected, multiple
immune mechanisms are identified (e.g., MHC Class I and II,
complement pathways, cytokines, and chemokines). In addition,
genes involved in regulation of the cytoskeleton, extracellular
matrix, metabolism, gene regulation, apoptosis, signal transduc-
tion, and stress response were identified. Importantly, diverse
regulatory mechanisms that could potentially coordinate the reg-
ulation of these mechanisms were also identified including reg-
ulators of transcription, RNA processing, splicing and stability,
translation, nuclear transport, chromatin remodeling and epige-
netic modifications. The subnetworks and pathways depicted in
our analyses identify some of the molecular interactions that may
regulate and coordinate the biological systems in TCMR.
Bunnag et al. analyzed the relationship between the molecular
expression, histopathology, and renal function in kidney trans-
plant biopsies with low GFR using microarray technology. They
analyzed transcripts differentially expressed in patients with low
versus high GFR. They noted that the highest expressed were
tissue injury transcripts, whereas the lowest expressed were the
kidney parenchyma transcripts (23). Genes which were highly
expressed in the tissue injury pathway included integrins, ker-
atin genes and a metalloproteinase gene (MMP7) were noted in
our TCMR02 group. This indicates that our analysis of rejection
subtypes identifies some of the same genes. A major difference
between the studies is that the study population analyzed by Bun-
nag et al. only included 13% biopsy proven TCMR. Einecke et al.
investigated whether there is a specific transcriptome indicative of
organ failure when the biopsy is performed 1 year after transplan-
tation. A direct analysis between our gene data set and their gene
data set shows a 50% shared genes in the core andTCMR01 groups
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and 37% with the TCMR02 group (SupplementaryMaterial) (17).
Their study population had multiple causes of graft failure and
only 13% had TCMR. The authors developed a gene expression
risk scorewhichwas predictive of graft failure in biopsies of kidney
transplants greater than 1 year after transplantation. Their analysis
differs from ours as they did not focus on TCMR but rather
analyzed all biopsies with graft dysfunction. As expected, the
genes associated with graft failure had functions related to tissue
injury. Sarwal et al. analyzed microarray data from 59 pediatric
renal allograft biopsies with poor function. They identified three
different signatures of the transcriptome although the samples
were indistinguishable by light microscopy (24). Their study re-
emphasizes the need to establish a genetic classification which will
aid in the management of TCMR, which is the problem our study
addressed. We analyzed microarray data of only TCMR biopsies
and classified the results into two major subtypes according to
their functional pathways. Our detailed approach allowed us to
identify specific pathways, which may be targeted in the future
with specific therapies for TCMR01 or TCMR02 subtype of rejec-
tion. This new classification could provide specific therapeutic
targets for personalized treatment.
Our study identified two specific subtypes of rejection,
TCMR01 or TCMR02. As expected, we also identified drugs
that had putative targets in both subtypes. Interestingly, a
number of the drugs that were potential therapies are either
current or previous therapies (Muromonab, Alemtuzumab, and
Alefacept), are in clinical trials or are treatments for other
diseases including cancer (Abciximab, Gemtuzumab ozogam-
icin, Ibritumonab, sunitinib, Bevacizumab, CPG52364, mc0457,
mln518, ptk787, Ranibizumab, PDX, Efalizumab, and Natal-
izumab) (25–40). The fact that some of these agents have
been clinically effective in the treatment of rejection (e.g.,
Muromonab) supports the validity of the analysis and sug-
gests that it could be informative to develop clinical trials that
link therapeutic agents with a specific molecular classification,
either TCMR01 or TCMR02. In addition, future studies that
combine integrated omics analyses, e.g., combining proteomics,
metabolomics, etc., with transcriptomics could increase the power
of a systems analysis.
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